Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's disease, has announced its participation in two upcoming investor conferences in September 2025.
The company will participate in Citi's 2025 Biopharma Back to School Conference with a fireside chat on September 2 at 3:15 p.m. ET, and the Cantor Global Healthcare Conference 2025 with a fireside chat on September 5 at 9:10 a.m. ET. Both presentations will be available via webcast on the company's website for 90 days.
Acumen Pharmaceuticals (NASDAQ: ABOS), azienda biofarmaceutica in fase clinica impegnata nello sviluppo di terapie per il morbo di Alzheimer, ha annunciato la propria partecipazione a due conferenze per investitori previste a settembre 2025.
La società prenderà parte al Citi's 2025 Biopharma Back to School Conference con un intervento in formato fireside chat il 2 settembre alle 15:15 ET, e al Cantor Global Healthcare Conference 2025 con un altro fireside chat il 5 settembre alle 9:10 ET. Entrambe le presentazioni saranno disponibili in webcast sul sito aziendale per 90 giorni.
Acumen Pharmaceuticals (NASDAQ: ABOS), una compañía biofarmacéutica en fase clínica dedicada al desarrollo de tratamientos para la enfermedad de Alzheimer, ha anunciado su participación en dos próximas conferencias para inversores en septiembre de 2025.
La compañía participará en el Citi's 2025 Biopharma Back to School Conference con una charla fireside el 2 de septiembre a las 3:15 p.m. ET, y en el Cantor Global Healthcare Conference 2025 con una charla fireside el 5 de septiembre a las 9:10 a.m. ET. Ambas presentaciones estarán disponibles en webcast en la página web de la compañía durante 90 días.
Acumen Pharmaceuticals (NASDAQ: ABOS)는 알츠하이머병 치료제 개발에 주력하는 임상 단계의 바이오제약사로, 2025년 9월에 개최되는 두 건의 투자자 컨퍼런스에 참가한다고 발표했습니다.
회사는 Citi's 2025 Biopharma Back to School Conference에서 9월 2일 오후 3시 15분(동부시간)에 파이어사이드 채트로 발표하며, Cantor Global Healthcare Conference 2025에서는 9월 5일 오전 9시 10분(동부시간)에 파이어사이드 채트로 발표합니다. 두 발표 모두 회사 웹사이트를 통해 90일간 웹캐스트로 제공됩니다.
Acumen Pharmaceuticals (NASDAQ: ABOS), une société biopharmaceutique en phase clinique dédiée au développement de traitements contre la maladie d'Alzheimer, a annoncé sa participation à deux conférences investisseurs prévues en septembre 2025.
La société participera au Citi's 2025 Biopharma Back to School Conference avec un entretien au format fireside chat le 2 septembre à 15h15 ET, et au Cantor Global Healthcare Conference 2025 avec un fireside chat le 5 septembre à 9h10 ET. Les deux présentations seront disponibles en webcast sur le site de la société pendant 90 jours.
Acumen Pharmaceuticals (NASDAQ: ABOS), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung von Therapien gegen die Alzheimer-Krankheit konzentriert, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im September 2025 angekündigt.
Das Unternehmen wird am Citi's 2025 Biopharma Back to School Conference mit einem Fireside-Chat am 2. September um 15:15 Uhr ET teilnehmen und am Cantor Global Healthcare Conference 2025 mit einem Fireside-Chat am 5. September um 09:10 Uhr ET. Beide Präsentationen werden für 90 Tage per Webcast auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
NEWTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in the following upcoming investor conferences.
Citi’s 2025 Biopharma Back to School Conference
Date/Time: Fireside chat on Tuesday, September 2, 2025 at 3:15 p.m. ET
Cantor Global Healthcare Conference 2025
Date/Time: Fireside chat on Friday, September 5, 2025 at 9:10 a.m. ET
The live webcasts may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme’s proprietary ENHANZE® drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery (EBD™) therapy for Alzheimer’s disease utilizing a transferrin-receptor-targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.
Investors:
Alex Braun
abraun@acumenpharm.com
Media:
AcumenPR@westwicke.com
FAQ
When is Acumen Pharmaceuticals (NASDAQ: ABOS) presenting at Citi's Biopharma Conference 2025?
What time is Acumen's presentation at the Cantor Global Healthcare Conference 2025?
Where can investors access Acumen Pharmaceuticals' (ABOS) conference presentations?
What is Acumen Pharmaceuticals' (ABOS) main focus in drug development?
